Talk:Enumeral
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||
| ||||||||||||||||||
CorpDepth review of citations[edit]
 | Parts of this article (those related to this section) need to be updated. Please help update this article to reflect recent events or newly available information. Relevant discussion may be found on the talk page. (July 2018) |
This review of the citations associated with the article as of 18 July 2016 does not bode well for retention of the article. As of this date, it would not survive an WP:AfD. --User:Ceyockey (talk to me) 03:06, 19 July 2018 (UTC)
| Source | Significant? | Independent? | Reliable? | Secondary | pass/fail | Cite # | Notes |
|---|---|---|---|---|---|---|---|
| Keown 2018 (Biospace) | Y | Y | Y | Y | Y | ||
| 10-Q | Y | N | Y | N | F | This is an excerpt from a republished segment of an SEC quarterly report. | |
| Enumeral PR 2014 | Y | N | Y | Y | F | Significant as it relates completion of merger activity | |
| Nature Biotechnology 2006 | N | Y | Y | Y | F | Not significant with respect to Company information, though likely otherwise significant | |
| Clinical Immunology 2009 | N | Y | Y | Y | F | ||
| PNAS 2008 | N | Y | Y | Y | F | ||
| Lab Chip 2011 | N | Y | Y | Y | F | ||
| J. of Clinical Invest. 2011 | N | Y | Y | Y | F | ||
| Integrative Biology 2013 | N | Y | Y | Y | F | ||
| Nature Immunology 2014 | N | Y | Y | Y | F | ||
| Nature 2014 | N | Y | Y | Y | F | ||
| Nature Biotechnology 2014 | N | Y | Y | Y | F | ||
| Scientific Advisory Board link | Y | N | Y | Y | F | self-published source, likely reliable | |
| Enumeral PR 2015 | N | N | Y | Y | F | Not significant with respect to Company info. | |
| Enumeral PR 2015 | N | N | Y | Y | F | ||
| Enumeral PR 2015 | N | N | Y | Y | F | ||
| Enumeral PR 2015 | Y | N | Y | Y | F | Significant in that relates changes in Advisory Board | |
| Enumeral PR 2014 | N | N | Y | Y | F | Speaks to a collaboration with a major Pharma; significant on its face - but not really unless it has significant impact on the company ... which cannot be said at the start of a collab. | |
| Enumeral PR 2015 | N | N | Y | Y | F | Speaks to meeting a milestone in collab with Merck ... but it doesn't specify the nature of the milestone or the amount of the milestone payment, either of which could have led to Y for significance. | |
| Total qualifying sources | 1 | There must be multiple qualifying sources to meet the notability requirements | |||||